HDAC9 and acute respiratory distress syndrome: Repurposing HDAC inhibitors for ARDS treatment is of great interest due to their ability to suppress pro-inflammatory gene expression, reduce NET release, and the promising results in preclinical mouse models, as shown in Figure 3.